【査読付き英文論文】

*1. Saloura V, Vougiouklakis T, Zewde M, Suzuki T, Dohmae N, Deng X, Kiyotani K, Park J-H, Matsuo Y, Lingen M, Hamamoto R, Nakamura Y: WHSC1L1-mediated EGFR mono-methylation enhances the cytoplasmic and nuclear oncogenic activity of EGFR. Scientific Reports, 7, 40664 (2017) [pubmed]

*2. Toyokawa G, Takada K, Okamoto T, Kozuma Y, Matsubara T, Haratake N, Akamine T, Takamori S, Katsura M, Shoji F, Hamamoto R, Oda Y, Maehara Y: Elevated metabolic activity on ¹⁸F-FDG PET/CT defines EZH2-expressing non-small cell lung cancer. Anticancer Research, 37, 1393-1401 (2017) [pubmed]

*3. Oki S, Sone K, Oda K, Hamamoto R, Ikemura M, Maeda D, Takeuchi M, Tanikawa M, Mori-Uchino M, Nagasaka K, Miyasaka A, Kashiyama T, Ikeda Y, Arimoto T, Kuramoto H, Wada-Hiraike O, Kawana K, Fukayama M, Osuga Y, Fujii T: Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancer. Oncotarget, 8, 40402-40411 (2017) [pubmed]

*4．Chiyoda T, Hart PC, Eckert MA, McGregor SM, Lastra RR, Hamamoto R, Nakamura Y, Yamada SD, Olopade OI, Lengyel E, Romero IL: Loss of BRCA1 in the cells of origin of ovarian cancer induces glycolysis: A window of opportunity for ovarian cancer chemoprevention. Cancer Prevention Research, 10, 255-266 (2017) [pubmed]

*5．Wang R, Deng X, Yoshioka Y, Vougiouklakis T, Park JH, Suzuki T, Dohmae N, Ueda K, Hamamoto R, Nakamura Y: Effects of SMYD2-mediated EML4-ALK methylation on the signaling pathway and growth in non-small cell lung cancer cells. Cancer Science, 18:1203-1209 (2017) [pubmed]

*6.  Kunizaki M, Fukuda A, Wakata K, Tominaga T, Nonaka T, Miyazaki T, Matsumoto K, Sumida Y, Hidaka S, Yasutake T, Sawai T, Hamamoto R, Nanashima A, Nagayasu T. Clinical Significance of Serum p53 Antibody in the Early Detection and Poor Prognosis of Gastric Cancer. Anticancer Research, 37, 1979-1984 (2017) [pubmed]

*7．Deng X, Hamamoto R, Vougiouklakis T, Wang R, Yoshioka Y, Suzuki T, Dohmae N, Matsuo Y, Park JH, Nakamura Y. Critical roles of SMYD2-mediated β-catenin methylation for nuclear translocation and activation of Wnt signaling. Oncotarget, 8, 55837-55847 (2017) [pubmed]

*8．*Yoshioka Y, Suzuki T, Matsuo Y, Tsurita G, Watanabe T, Dohmae N, Nakamura Y, Hamamoto R. Protein lysine methyltransferase SMYD3 is involved in tumorigenesis through regulation of HER2 homodimerization. Cancer Medicine, 6, 1665-1672 (2017) [pubmed]